HemoShear Therapeutics

OverviewSuggest Edit

HemoShear is a company discovering treatments for rare metabolic disorders in children. Its technology helps to recapitulate diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates with high probabilities of clinical success.
TypePrivate
Founded2008
HQCharlottesville, US
Websitehemoshear.com

Locations

HemoShear Therapeutics is headquartered in
Charlottesville, United States

Location Map

Latest Updates

Employees (est.) (Oct 2020)43(-2%)
Cybersecurity ratingAMore

Key People/Management at HemoShear Therapeutics

James Powers

James Powers

Chairman and CEO
Brian A. Johns

Brian A. Johns

Chief Scientific Officer
Aric Holsinger

Aric Holsinger

Chief Financial Officer
Mark Hayes

Mark Hayes

Acting Chief Regulatory Officer
Robert J. Gould

Robert J. Gould

Board Member
Kathleen M. Metters

Kathleen M. Metters

Board Member
Show more

HemoShear Therapeutics Office Locations

HemoShear Therapeutics has an office in Charlottesville
Charlottesville, US (HQ)
501 Locust Ave #301
Show all (1)

HemoShear Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2008

HemoShear Therapeutics total Funding

$11.7 m

HemoShear Therapeutics latest funding size

$8.70 m

Time since last funding

6 years ago
HemoShear Therapeutics's latest funding round in May 2014 was reported to be $8.7 m. In total, HemoShear Therapeutics has raised $11.7 m
Show all financial metrics

HemoShear Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

HemoShear Therapeutics Online and Social Media Presence

Embed Graph

HemoShear Therapeutics News and Updates

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

CHARLOTTESVILLE, Va., Oct. 21, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has entered into a research collaboration and service agreement with Takeda Pharmaceutical Company Limited ("Takeda"). Under the terms of the agreement,...

HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia

CHARLOTTESVILLE, Va., July 28, 2020 /PRNewswire/ -- HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for HST5040, a...

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

CHARLOTTESVILLE, Va., June 24, 2020 /PRNewswire/ -- HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a...

HemoShear Therapeutics Frequently Asked Questions

  • When was HemoShear Therapeutics founded?

    HemoShear Therapeutics was founded in 2008.

  • Who are HemoShear Therapeutics key executives?

    HemoShear Therapeutics's key executives are James Powers, Brian A. Johns and Aric Holsinger.

  • How many employees does HemoShear Therapeutics have?

    HemoShear Therapeutics has 43 employees.

  • Who are HemoShear Therapeutics competitors?

    Competitors of HemoShear Therapeutics include TetraGenetics, Malin and Capstone Therapeutics.

  • Where is HemoShear Therapeutics headquarters?

    HemoShear Therapeutics headquarters is located at 501 Locust Ave #301, Charlottesville.

  • Where are HemoShear Therapeutics offices?

    HemoShear Therapeutics has an office in Charlottesville.

  • How many offices does HemoShear Therapeutics have?

    HemoShear Therapeutics has 1 office.